Blueprint Medicines begins phase 1 trial of RET inhibitor, BLU-667 to treat patients with NSCLC, MTC and advanced solid tumors

Blueprint Medicines Corporation, a leader in discovering and developing targeted kinase medicines for patients with genomically defined diseases, has dosed the first patient in a phase 1 clinical trial of BLU-667, an investigational RET inhibitor for patients with non-small cell lung cancer (NSCLC), medullary thyroid cancer (MTC) and other advanced solid tumors that harbor a RET alteration.